Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants

Archive ouverte

Khera, Tanvi | Behrendt, Patrick | Bankwitz, Dorothea | Brown, Richard J. P. | Todt, Daniel | Doepke, Mandy | Khan, Abdul Ghafoor | Schulze, Kai | Law, John | Logan, Michael | Hockman, Darren | Wong, Jason Alexander Ji-Xhin | Dold, Leona | Gonzalez Motos, Victor | Spengler, Ulrich | Viejo-Borbolla, Abal | Stroh, Luisa J. | Krey, Thomas | Tarr, Aalexander W. | Steinmann, Eike | Manns, Michael P. | Klein, Florian | Guzman, Carlos A. | Marcotrigiano, Joseph | Houghton, Michael | Pietschmann, Thomas

Edité par CCSD ; Elsevier -

BACKGROUND & AIMS: Induction of cross-reactive antibodies targeting conserved epitopes of the envelope proteins E1E2 is a key requirement for an hepatitis C virus vaccine. Conserved epitopes like the viral CD81-binding site are targeted by rare broadly neutralizing antibodies. However, these viral segments are occluded by variable regions and glycans. We aimed to identify antigens exposing conserved epitopes and to characterize their immunogenicity. METHODS: We created hepatitis C virus variants with mutated glycosylation sites and/or hypervariable region 1 (HVR1). Exposure of the CD81 binding site and conserved epitopes was quantified by soluble CD81 and antibody interaction and neutralization assays. E2 or E1-E2 heterodimers with mutations causing epitope exposure were used to immunize mice. Vaccine-induced antibodies were examined and compared with patient-derived antibodies. RESULTS: Mutant viruses bound soluble CD81 and antibodies targeting the CD81 binding site with enhanced efficacy. Mice immunized with E2 or E1E2 heterodimers incorporating these modifications mounted strong, cross-binding, and non-interfering antibodies. E2-induced antibodies neutralized the autologous virus but they were not cross-neutralizing. CONCLUSIONS: Viruses lacking the HVR1 and selected glycosylation sites expose the CD81 binding site and cross-neutralization antibody epitopes. Recombinant E2 proteins carrying these modifications induce strong cross-binding but not cross-neutralizing antibodies. LAY SUMMARY: Conserved viral epitopes can be made considerably more accessible for binding of potently neutralizing antibodies by deletion of hypervariable region 1 and selected glycosylation sites. Recombinant E2 proteins carrying these mutations are unable to elicit cross-neutralizing antibodies suggesting that exposure of conserved epitopes is not sufficient to focus antibody responses on production of cross-neutralizing antibodies.

Consulter en ligne

Suggestions

Du même auteur

Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2

Archive ouverte | Vasiliauskaite, Ieva | CCSD

International audience. ABSTRACT The hepatitis C virus (HCV) glycoprotein E2 is the major target of neutralizing antibodies and is therefore highly relevant for vaccine design. Its structure features a central immun...

A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1

Archive ouverte | Johnson, Janelle | CCSD

The global health burden for hepatitis C virus (HCV) remains high, despite available effective treatments. To eliminate HCV, a prophylactic vaccine is needed. One major challenge in the development of a vaccine is the genetic dive...

Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication

Archive ouverte | Todt, Daniel | CCSD

International audience. Hepatitis E virus (HEV) is the causative agent of hepatitis E in humans and a member of the genus Orthohepevirus in the family Hepeviridae. HEV infections are the common cause of acute hepati...

Chargement des enrichissements...